C12Y 304/21068
Tissue plasminogen activator , i.e. tpa
Official title: Tissue plasminogen activator (3.4.21.68), i.e. tPA
C12Y304/21068 (Tissue plasminogen activator , i.e. tpa) appears on 106 US grants and 181 published applications in this corpus.
Search patents in C12Y- Granted patents
- 106
- Published applications
- 181
- Assignees
- 110
- Inventors
- 260
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 2 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 2 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 1 |
| 2003 | 1 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 1 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 3 |
| 2010 | 0 | 2 |
| 2011 | 2 | 1 |
| 2012 | 3 | 8 |
| 2013 | 2 | 4 |
| 2014 | 3 | 9 |
| 2015 | 4 | 14 |
| 2016 | 4 | 13 |
| 2017 | 5 | 11 |
| 2018 | 10 | 8 |
| 2019 | 8 | 16 |
| 2020 | 13 | 13 |
| 2021 | 7 | 13 |
| 2022 | 8 | 7 |
| 2023 | 3 | 17 |
| 2024 | 5 | 17 |
| 2025 | 6 | 10 |
| 2026 | 5 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of treating ischemic disease by administering an ATR kinase inhibitor22 Sep 2026US 12,740,980 B2East Tennessee State University Research Foundation
- Methods, compositions, and devices for drug / live cell microarrays19 May 2026US 12,629,345 B2Pathak Holdings LLC
- Thrombolytic agents for intravascular clots14 Apr 2026US 12,599,653 B2Jinis Co., Ltd.
- Methods for safe and effective thrombolysis using sequential administration of tissue plasminogen activator and mutant pro-urokinase31 Mar 2026US 12,590,301 B2Thrombolytic Science, Inc.
- Medical use of icaritin24 Feb 2026US 12,558,343 B2Lunan Pharmaceutical Group Corporation
- Methods, compositions, and devices for drug or live cell microarrays27 Aug 2026US 2026/0248746 A1Pathak Holdings LLC
- Method of preventing and/or treating tissue damage or injury18 Jun 2026US 2026/0166009 A1Morehouse School of Medicine
- Method for promoting pathological tdp-43 protein degradation, and drug18 Jun 2026US 2026/0166131 A1Talengen International Limited
- Method and drug for promoting removal of pathological proteins by ubiquitin proteasome system and autophagy lysosome system18 Jun 2026US 2026/0166132 A1Talengen International Limited
- Use of Tetramethylpyrazine Nitrone Derivatives In The Treatment of Ischemic Stroke4 Jun 2026US 2026/0151389 A1Guangzhou Magpie Pharmaceuticals Co., Ltd.
Most cited
By later US patents
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers217US 5,626,863 ABoard of Regents, The University of Texas System · 1997
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers207US 5,567,435 ABoard of Regents, The University of Texas System · 1996
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers145US 6,060,582 ABoard of Regents, The University of Texas System · 2000
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers116US 5,986,043 ABoard of Regents, The University of Texas System · 1999
- Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers111US 6,306,922 B1Boards of Regents, The University of Texas System · 2001